PT2035029T - Compostos peptídicos para o tratamento de status epilepticus refratário - Google Patents

Compostos peptídicos para o tratamento de status epilepticus refratário

Info

Publication number
PT2035029T
PT2035029T PT77646784T PT07764678T PT2035029T PT 2035029 T PT2035029 T PT 2035029T PT 77646784 T PT77646784 T PT 77646784T PT 07764678 T PT07764678 T PT 07764678T PT 2035029 T PT2035029 T PT 2035029T
Authority
PT
Portugal
Prior art keywords
peptide compounds
status epilepticus
refractory status
treating refractory
treating
Prior art date
Application number
PT77646784T
Other languages
English (en)
Inventor
Stöhr Thomas
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36889233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2035029(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of PT2035029T publication Critical patent/PT2035029T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT77646784T 2006-06-15 2007-06-15 Compostos peptídicos para o tratamento de status epilepticus refratário PT2035029T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81396706P 2006-06-15 2006-06-15
EP06013655A EP1873527A1 (en) 2006-06-30 2006-06-30 Method for identifying CRMP modulators

Publications (1)

Publication Number Publication Date
PT2035029T true PT2035029T (pt) 2017-02-03

Family

ID=36889233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77646784T PT2035029T (pt) 2006-06-15 2007-06-15 Compostos peptídicos para o tratamento de status epilepticus refratário

Country Status (21)

Country Link
US (3) US20100273714A1 (pt)
EP (2) EP1873527A1 (pt)
JP (1) JP5795145B2 (pt)
KR (2) KR101517133B1 (pt)
CN (3) CN101636180B (pt)
AR (1) AR061475A1 (pt)
AU (1) AU2007260208B2 (pt)
BR (1) BRPI0713702A2 (pt)
CA (1) CA2651684C (pt)
CY (1) CY1118523T1 (pt)
DK (1) DK2035029T3 (pt)
EA (1) EA018607B1 (pt)
ES (1) ES2613931T3 (pt)
HU (1) HUE033180T2 (pt)
LT (1) LT2035029T (pt)
MX (1) MX2008015951A (pt)
PL (1) PL2035029T3 (pt)
PT (1) PT2035029T (pt)
SI (1) SI2035029T1 (pt)
TW (1) TWI422384B (pt)
WO (1) WO2007144196A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
NZ550482A (en) * 2004-04-16 2010-08-27 Sanol Arznei Schwarz Gmbh Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
BRPI0514721A (pt) * 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
KR101518427B1 (ko) 2006-06-15 2015-05-08 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
CA2774569A1 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2378291A1 (en) 2010-04-15 2011-10-19 UCB Pharma GmbH Lacosamide detection assay
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2645997B1 (en) 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide
US20150259740A1 (en) * 2011-09-14 2015-09-17 Harvey Pollard Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder
CN108697662A (zh) * 2015-12-11 2018-10-23 奥胡斯大学 用于治疗肌强直的卢非酰胺
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023178250A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of tuberous sclerosis with mirdametinib

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US813967A (en) 1905-07-27 1906-02-27 John W Hart Self-igniting match-safe.
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
DK1038522T3 (da) 1996-03-15 2004-10-11 Res Corp Technologies Inc Antikonvulsive enantiomere aminosyrederivater
DE60006618T2 (de) * 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
GB9926898D0 (en) * 1999-11-12 2000-01-12 School Of Earth & Environmenta Calcium silicate sorbents
MXPA03001458A (es) * 2000-08-17 2004-05-04 Teva Pharma Derivados de acido valproico para el tratamiento del dolor.
US20020119944A1 (en) * 2000-11-09 2002-08-29 Michelle Aguera Use of Ulip-and/or Ulip2 in the treatment of myelin disorders
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
CA2461692A1 (fr) * 2001-09-07 2003-03-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1541138A1 (en) * 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
NZ550482A (en) * 2004-04-16 2010-08-27 Sanol Arznei Schwarz Gmbh Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
BRPI0514721A (pt) * 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
WO2006079547A2 (en) 2005-01-28 2006-08-03 Schwarz Pharma Ag Spm 927 for add-on therapy of schizophrenia
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
KR101518427B1 (ko) * 2006-06-15 2015-05-08 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
EP2645997B1 (en) * 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide

Also Published As

Publication number Publication date
ES2613931T3 (es) 2017-05-29
HUE033180T2 (en) 2017-11-28
CY1118523T1 (el) 2017-07-12
AU2007260208A1 (en) 2007-12-21
CN101636180A (zh) 2010-01-27
CN101489591B (zh) 2013-09-11
PL2035029T3 (pl) 2017-05-31
EP2035029B1 (en) 2016-11-30
KR20140042926A (ko) 2014-04-07
KR20090030307A (ko) 2009-03-24
US20100273714A1 (en) 2010-10-28
KR101517133B1 (ko) 2015-05-04
DK2035029T3 (en) 2017-01-23
TW200815024A (en) 2008-04-01
TWI422384B (zh) 2014-01-11
CA2651684C (en) 2017-09-12
JP2009539910A (ja) 2009-11-19
JP5795145B2 (ja) 2015-10-14
EP1873527A1 (en) 2008-01-02
WO2007144196A3 (en) 2008-08-21
EP2035029A2 (en) 2009-03-18
MX2008015951A (es) 2009-01-12
AU2007260208B2 (en) 2012-04-12
LT2035029T (lt) 2017-02-10
CA2651684A1 (en) 2007-12-21
US20140128377A1 (en) 2014-05-08
US20140128378A1 (en) 2014-05-08
CN101489591A (zh) 2009-07-22
EA018607B1 (ru) 2013-09-30
CN101636180B (zh) 2012-11-28
WO2007144196A2 (en) 2007-12-21
AR061475A1 (es) 2008-08-27
CN103751157A (zh) 2014-04-30
BRPI0713702A2 (pt) 2012-10-30
EA200900021A1 (ru) 2009-06-30
SI2035029T1 (sl) 2017-03-31

Similar Documents

Publication Publication Date Title
PT2035029T (pt) Compostos peptídicos para o tratamento de status epilepticus refratário
EG25849A (en) Composition for treating textile
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
PL1999312T3 (pl) Powłoka ceramiczna dla materiału włókienniczego
IL198851A0 (en) Methods for treating hypercholesterolemia
EP1955987A4 (en) CHAMOTTE STONE
HK1131577A1 (en) Compositions for treating cancer
IL190991A0 (en) Agents for treating cardiopathy
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
EP2089048A4 (en) COMPOSITION FOR CARTILAGE
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
ZA200904053B (en) Phosphonate compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
EP2097408A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF EPROSARTAN
TWI367274B (en) Composition for fabric treatment
ZA200900040B (en) Cement-free refractory
EP2082022A4 (en) COMPOUNDS
ZA200902830B (en) Solid composition for treating water
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
EP1973905A4 (en) COMPOUNDS
GB2441892B (en) Histofluorescent stain for endoscopy
GB2433911B (en) Chisels
ZA200903242B (en) Treatment for multiple myeloma
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN